RxDoctor Payments Data

Nimrod Lavi, MD

Cardiovascular Disease · New Haven, CTNPI 1477641264

Payments from drug & device makers

$6,042in general payments, 2019–2025

Across 59 payments — averaging $102.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$4K
  • Medtronic$878
  • Biosense Webster, Inc.$625
  • E.r. Squibb & Sons, L.L.C.$141
  • Novartis$126
  • Novo Nordisk$67
  • plus $185 from 6 others

What the payments were for

  • Speaking & faculty fees$4,00066%
  • Travel & lodging$62210%
  • Food & beverage$1,42024%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,042 in reported general payments places this provider in the 70th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$219,714
Medicare patients
1,281
Services billed
3,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban265$373,432
XareltoRivaroxaban119$150,743
OzempicSemaglutide70$90,285
MounjaroTirzepatide64$73,678
EntrestoSacubitril/Valsartan29$28,099
WegovySemaglutide17$22,796
Metoprolol Succinate411$8,710
Dofetilide31$8,524
Mexiletine Hcl32$6,795
Diltiazem 24hr Er (Cd)Diltiazem Hcl141$4,814
Flecainide Acetate79$4,006
Amiodarone Hcl80$2,827
Nadolol38$1,559
Metoprolol Tartrate160$1,210
SotalolSotalol Hcl34$971

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$373,432265 claims
Johnson & JohnsonXarelto$18$150,743119 claims
Novo NordiskOzempic, Wegovy$67$113,08187 claims
NovartisEntresto$126$28,09929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →